CompletedPhase 2

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

United States5 participantsStarted 2016-09-13

Plain-language summary

This clinical trial studies how well 18F-fluoromisonidazole (\[18F\]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. \[18F\]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by \[18F\]FMISO is picked up by a PET scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Histopathologic or imaging and clinical features of tumor(s) diagnostic for hepatocellular carcinoma with at least one tumor \>= 1.5 cm; imaging features diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and Data System (LIRADS) 4 or greater * Total bilirubin \< 3.0 * Child Pugh A or B * Tumor amenable to transcatheter arterial embolization * Able to provide informed consent Exclusion Criteria: * Uncontrolled large ascites * Main or segmental portal vein thrombosis * Locoregional treatment of hepatocellular carcinoma within the prior 3 months or chemotherapy within the previous 3 months * Inability or contraindication to undergo transcatheter arterial embolization * Inability to lay flat for at least 2 consecutive hours * Severe acute illness * Uncontrolled chronic illness such as hypertension, diabetes, or heart failure * Contraindication to CT or MRI contrast * Pregnancy

What they're measuring

Post-treatment Maximum Standardized Uptake Value (SUVmax) in Tumor and Normal Tissue

Timeframe: 24 hours

Trial details

NCT IDNCT02695628

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-04-30

Results submitted2019-03-13